WO2004039796A1 - Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren - Google Patents
Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren Download PDFInfo
- Publication number
- WO2004039796A1 WO2004039796A1 PCT/EP2003/011452 EP0311452W WO2004039796A1 WO 2004039796 A1 WO2004039796 A1 WO 2004039796A1 EP 0311452 W EP0311452 W EP 0311452W WO 2004039796 A1 WO2004039796 A1 WO 2004039796A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- substituted
- hydrogen
- alkoxy
- mmol
- Prior art date
Links
- 0 Cc1c(c(*)c[n]2)c2ncc1 Chemical compound Cc1c(c(*)c[n]2)c2ncc1 0.000 description 10
- YFNIGSJHKGKXEQ-UHFFFAOYSA-O COc1c2c(N)[nH+][o]c2ccc1 Chemical compound COc1c2c(N)[nH+][o]c2ccc1 YFNIGSJHKGKXEQ-UHFFFAOYSA-O 0.000 description 1
- CXGQGMOLYRKMNR-UHFFFAOYSA-N Cc1n[nH]c2c1c(Oc(ccc(Nc1cc(-c3ccncc3)nc(N)n1)c1)c1F)ccc2 Chemical compound Cc1n[nH]c2c1c(Oc(ccc(Nc1cc(-c3ccncc3)nc(N)n1)c1)c1F)ccc2 CXGQGMOLYRKMNR-UHFFFAOYSA-N 0.000 description 1
- KIMSETFIPUOZBQ-UHFFFAOYSA-N Nc(cc1)cc(F)c1Oc1c(cn[nH]2)c2ccc1 Chemical compound Nc(cc1)cc(F)c1Oc1c(cn[nH]2)c2ccc1 KIMSETFIPUOZBQ-UHFFFAOYSA-N 0.000 description 1
- ZBDBQIBGOSSPGF-UHFFFAOYSA-N Nc(cc1F)cc(F)c1OC1=C(C=CN2)C2=NCC1 Chemical compound Nc(cc1F)cc(F)c1OC1=C(C=CN2)C2=NCC1 ZBDBQIBGOSSPGF-UHFFFAOYSA-N 0.000 description 1
- FQDLJNWPVVKYAT-UHFFFAOYSA-N Nc(cc1F)cc(F)c1Oc1cc(Cl)nc2c1cc[nH]2 Chemical compound Nc(cc1F)cc(F)c1Oc1cc(Cl)nc2c1cc[nH]2 FQDLJNWPVVKYAT-UHFFFAOYSA-N 0.000 description 1
- YPPFUPCXFIIKQD-UHFFFAOYSA-N Nc1n[o]c2cccc(O)c12 Chemical compound Nc1n[o]c2cccc(O)c12 YPPFUPCXFIIKQD-UHFFFAOYSA-N 0.000 description 1
- JSXLBQGRILWFAY-UHFFFAOYSA-N Nc1nc(C2CCCCC2)cc(Cl)n1 Chemical compound Nc1nc(C2CCCCC2)cc(Cl)n1 JSXLBQGRILWFAY-UHFFFAOYSA-N 0.000 description 1
- YSZNXQZUEJNPBS-UHFFFAOYSA-N Nc1nc(Cl)cc(C(CCC2)CN2C(OCc2ccccc2)=O)n1 Chemical compound Nc1nc(Cl)cc(C(CCC2)CN2C(OCc2ccccc2)=O)n1 YSZNXQZUEJNPBS-UHFFFAOYSA-N 0.000 description 1
- MLRBPAYJOZZPLV-UHFFFAOYSA-N Nc1nc(Nc(cc2)cc(F)c2Oc2c(cc[nH]3)c3ncc2)cc(Cl)n1 Chemical compound Nc1nc(Nc(cc2)cc(F)c2Oc2c(cc[nH]3)c3ncc2)cc(Cl)n1 MLRBPAYJOZZPLV-UHFFFAOYSA-N 0.000 description 1
- SDPJMHFXJNSQFE-UHFFFAOYSA-N Nc1nc(Nc(cc2)cc(F)c2Oc2ccnc3c2cc[nH]3)cc(-c(cc2)ccc2F)n1 Chemical compound Nc1nc(Nc(cc2)cc(F)c2Oc2ccnc3c2cc[nH]3)cc(-c(cc2)ccc2F)n1 SDPJMHFXJNSQFE-UHFFFAOYSA-N 0.000 description 1
- SOPJOTICOLWXOJ-UHFFFAOYSA-O Nc1nc(Nc(cc2F)ccc2Oc2ccnc3c2cc[nH]3)cc(CCCC(N2CCCCC2)=O)[nH+]1 Chemical compound Nc1nc(Nc(cc2F)ccc2Oc2ccnc3c2cc[nH]3)cc(CCCC(N2CCCCC2)=O)[nH+]1 SOPJOTICOLWXOJ-UHFFFAOYSA-O 0.000 description 1
- IOKLRUQDALYCPZ-UHFFFAOYSA-N Nc1nc(O)cc(-c2ccncc2)n1 Chemical compound Nc1nc(O)cc(-c2ccncc2)n1 IOKLRUQDALYCPZ-UHFFFAOYSA-N 0.000 description 1
- WOIAIVJWNRFBGP-UHFFFAOYSA-O [O-][N+](c(cc1)c(cc[nH]2)c2[n+]1O)=O Chemical compound [O-][N+](c(cc1)c(cc[nH]2)c2[n+]1O)=O WOIAIVJWNRFBGP-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the invention relates to heteroaryloxy-substituted phenylaminopvrimidines, a process for their preparation and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases in humans and animals, in particular cardiovascular diseases.
- Rho / Rho kinase signaling pathway (Noda, M. et al., FEBS Lett. 1995, 367, 246-250; Uehata, M. et al., Nature 1997, 389, 990-994; Fukata, Y. et 5 al., Trends in Pharmacological Sciences 2001, 22, 32-39). If agonists such as phenylephrine or thromboxane A2 bind to their receptors, this leads to the activation of the small G proteins Rho, which then interact with the Rho kinase and activate it.
- Rho-kinase inhibitors inhibit the myosin phosphatase after it has phosphorylated a subunit of the enzyme.
- Rho-kinase MLC phosphorylates at the site that is also phosphorylated by the MLC kinase. Inhibition of myosin phosphatase and phosphory- MLC induction induces contraction of the vascular muscles. In contrast, inhibition of Rho kinase leads to vascular relaxation. Rhokinase inhibitors therefore lower blood pressure and increase coronary blood flow.
- Rho-kinase inhibits the growth of tumor cells and metastases (Itoh et al. Nat. Med. 1999, 5, 221; Somlyo et al. Biochem. Biophys. Res. Commun. 2000, 269, 652) and inhibit angiogenesis (Uchida et al. Biochem. Biophys. Res. Commun. 2000, 269, 633; Gingras et al. Biochem. J. 2000, 348 Vol. 2, 273).
- pyrimidine derivatives are anti-cancer and anti-HIN agents (Debi, M .; Indian J. Exp. Biol. 1997, 35, 1208-1213) or as cdk2 inhibitors (WO-A 01/64654) described.
- the object of the present invention is to provide medicaments for the
- the present invention relates to compounds of the formula (I)
- X represents N or C-H
- Y represents N-R, O or S
- R 7 represents hydrogen, benzyl, phenyl, (C 1 -C 6 ) alkyl or (C 3 -C 8 cycloalkyl,
- alkyl and cycloalkyl in turn can be substituted by fluorine, hydroxyl, amino, carboxyl, (-d -alkoxy, (C 1 -C6) -alkylamino or morpholinyl),
- R represents hydrogen, halogen, trifluoromethyl, (C 1 -C 6) alkylamino or WR 7 ,
- wor W represents NH, O or a bond
- R 1 and R 2 independently of one another denote hydrogen, halogen or cyano
- R and R 4 independently of one another denote hydrogen, fluorine or chlorine
- R 5 represents a radical which is selected from the group of:
- R 8 and R 9 independently of one another are hydrogen, (CrC 8 ) -alkyl, (C 3 -C 6 ) -cycloalkyl optionally substituted by (CC 6 ) -alkyl, optionally substituted by halogen (C 6 -C 10 ) -aryl or 5 - are up to 10-membered heteroaryl or
- R 8 and R 9 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further hetero atom O or N in the ring and which is substituted by (Ci-C ⁇ ) - alkyl, (C ⁇ C ⁇ ) - alkanoyl or (C 1 -C 6 ) alkoxycarbonyl may be substituted,
- aryl, aryloxy, heteroaryl, heteroaryloxy and heterocyclyl in turn are substituted by halogen, cyano, nitro, carboxyl, amino, trifluoromethyl, optionally substituted by hydroxy (CrC ⁇ alkyl, (C ⁇ -C 6 ) alkoxy, (Cj-C 6 ) - Alkylamino, (CC 6 ) -alkanoyl, (CC 6 ) -alkoxycarbonyl, (CrC 6 ) -alkanoylamino, (C rC 6 ) -alkoxycarbonylamino or 5- or 6-membered heterocyclyl may be substituted,
- R 10 and R 11 independently of one another for hydrogen, (CrC ö ⁇ Alk l,
- alkyl and cycloalkyl in turn by hydroxy, (C Cö) - alkoxy, (C 6 -C ⁇ o) aryl, 5- to 10-membered heteroaryl or
- NR I5 R 16 can be substituted, worm
- R 15 and R 16 independently of one another represent hydrogen, (d-Cö) - alkyl, (C 3 -C 6 ) cycloalkyl, (C 6 -C 10 ) aryl or 5- or 6-membered heteroaryl
- R 15 and R 16 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further hetero atom O or N in the ring and which is substituted by (Ci-C ⁇ ) - alkyl, (C ⁇ -C 6 ) alkanoyl or (dC 6 ) alkoxycarbonyl may be substituted,
- Aryl and heteroaryl in turn by halogen, hydroxy, amino, cyano, trifluoromethyl, (dC 6 ) alkyl, (dC 6 ) -
- R 10 and R 11 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle, which may contain a further hetero atom O or N in the ring and which is fluorine, hydroxyl, carboxyl, 5- to 7 -linked heterocyclicl which may contain one or two further heteroatoms N and / or O in the ring and which in turn is obtained by (dC 4 ) - Alkyl or (dC 4) alkoxycarbonyl may be substituted, (dC 4) - alkoxy optionally substituted by hydroxy, (dC 4) - alkoxy or NR 17 R 18 substituted (dC) - alkyl, (CC 4) alkanoyl, (dC ⁇ alkoxycarbonyl or NR 12 R 13 may be substituted,
- R and R independently of one another are hydrogen, (dC 6 ) alkyl, (dC 4 ) alkoxycarbonyl, (C 3 -C 8 ) cycloalkyl 10 or (-C-C 4 ) alkanoyl
- R and R together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which can contain another hetero atom O or N in the ring and which is substituted by (dC 6 ) - alkyl, (dC 6 ) - Alkanoyl or (-CC 6 ) alkoxycarbonyl may be substituted,
- R 17 and R 18 independently of one another for hydrogen, optionally substituted by hydroxy (d-C ⁇ ) -
- R 17 and R 18 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle form, which may contain a further heteroatom O or N in the ring and which may be substituted by (dC ⁇ alkyl, (-C-C 6 ) alkanoyl or (C 1 -C 6 ) alkoxycarbonyl,
- R 10 and R 11 together with the nitrogen atom to which they are attached form a 7- to 12-membered bicyclic or tricyclic heterocycle which is fused or spirocyclic and one or two further heteroatoms from the series N and / or O in the ring can have and which can be substituted by fluorine, (-CC 4 ) -alkyl, (d-C) -alkoxycarbonyl, (dC) -alkanoyl or benzyl,
- Nitrogen-bonded 5- to 10-membered mono- or bicyclic heterocycle which is fused or spirocyclic and can have one or two further heteroatoms from the series N and / or O in the ring,
- alkylamino in turn can be substituted by a 5- or 6-membered heterocyclyl
- Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts; the compounds of the formulas encompassed by the formula (I) below and their salts, solvates and solvates of the salts, and the compounds encompassed by the formula (I) hereinafter referred to as exemplary embodiments and their salts, solvates and solvates of the salts, insofar as is possible the compounds mentioned below by formula (I) are not already salts, solvates and solvates of the salts.
- the compounds according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers).
- the invention therefore relates to the enantiomers or diastereomers and their respective mixtures.
- the stereoisomerically uniform constituents can be isolated in a known manner from such mixtures of enantiomers and / or diastereomers.
- the invention also relates to
- preferred salts are physiologically acceptable salts of the compounds according to the invention.
- Physiologically acceptable salts of compounds (I) include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ehanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid, trifluoroacetic acid and benzoic acid.
- Physiologically acceptable salts of the compounds (T) also include salts of conventional bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines with 1 to 16 ° C.
- alkali metal salts for example sodium and potassium salts
- alkaline earth metal salts for example calcium and magnesium salts
- E & ylamine diethylamine, triemylamine, ethyldiisopropylamine, monoemanolamine, diethanolamine, triethanolamine, dicyclo-hexylamine, dimemylaminoethanol, procaine, dibenzylamine, N-methylmorpholrn, dihydro-abiemylarnine, arginine-piperidine, lysine diamine.
- solvates are those forms of the compounds which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvate, in which coordination takes place with water.
- Alkoxycarbonyl alkoxycarbonylamino and alkanoylamino represent a linear or branched alkyl radical with generally 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms, by way of example and preferably methyl, ethyl, n-propyl, isopropyl, tert.- Butyl, n-pentyl and n-hexyl.
- Alkoxy is exemplary and preferably methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
- Alkanoyl is exemplary and preferably acetyl and propanoyl.
- Alkylamino stands for an alkylamino radical with one or two (independently selected) alkyl substituents, for example and preferably for methylamino, ethylamino, n-propylamino, isopropylarnino, tert-butylamino, n-pentylamino, n-hexylamino, NN-dimemylamino, NN -Diemylamino, NN-diisopropylamino, N- E yl-N-memylamino, N-Memyl-Nn-propylamino, N-isopropyl-Nn-propylamino, Nt-butyl-N-memylamino, N-Emyl-Nn-pentylarnino and Nn- hexyl-N-memylamino.
- C 4 -alkylamino is, for example, a monoalkylamino radical having 1 to 4 carbon atoms. atoms or for a dialkylamino radical each having 1 to 4 carbon atoms per alkyl substituent.
- Alkoxycarbonyl exemplifies and preferably represents methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxycarbonyl.
- Alkoxycarbonylamino is exemplified and preferably for memoxycarbonylamino, emoxycarbonylamino, n-propoxycarbonylamino, isopropoxycarbonylamino, tert-butoxycarbonylamino, n-pentoxycarbonylamino and n-hexoxycarbonylamino.
- Alkanoylamino is exemplary and preferably acetylamino and ethylcarbonylamino.
- Cycloalkyl stands for a cycloalkyl group with usually 3 to 8, preferably 5 to
- Aryl per se and in aryloxy stands for a mono- to tricyclic aromatic, carbocyclic radical with generally 6 to 14 carbon atoms; exemplary and preferably for phenyl, naphthyl and phenanthrenyl.
- Aryloxy is exemplary and preferably phenyloxy and naphthyloxy.
- Heteroaryl per se and in heteroaryloxy represents an aromatic, mono- or bicyclic radical with generally 5 to 10, preferably 5 to 6 ring atoms and up to 5, preferably up to 4 heteroatoms from the series S, O and N, for example and preferably for thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl.
- Heteroaryloxy is exemplary and preferably pyridyloxy, pyrimidyloxy, indolyloxy, indazolyloxy.
- Heterocyclyl and heterocycle stand for a mono- or polycyclic, preferably mono- or bicyclic, non-aromatic heterocyclic radical with 4 to 10, usually 5 to 8, preferably 5 or 6 ring atoms and up to 3, preferably up to 2 Heteroatoms and / or hetero groups from the series N, O, S, SO, SO 2 .
- the heterocyclyl residues can be saturated or partially unsaturated.
- 5- or 6-membered, monocyclic, saturated heterocyclyl radicals having up to two heteroatoms from the series O, N and S are preferred, such as, for example and preferably, tetrahydrofuran-2-yl, tetrahydrothienyl, pyrrolidin-2-yl, pyrrolidin-3-yl, Pyrrolinyl, pyranyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, thiopyranyl, morpholin-1-yl, morpholin-2-yl, morpholin-3-yl, perhydroazepinyl, Piperazin-1-yl, piperazin-2-yl.
- Halogen stands for fluorine, chlorine, bromine and iodine.
- radicals in the compounds according to the invention are substituted, the radicals, unless otherwise specified, can be substituted one or more times in the same or different manner.
- a substitution with up to three identical or different ones can be substituted one or more times in the same or different manner.
- R 6 represents hydrogen, (dC 4 ) -alkyl or NH-R 7 ,
- R 7 represents hydrogen or (CC 4 ) alkyl
- R and R independently of one another denote hydrogen, fluorine or chlorine
- R and R independently of one another denote hydrogen or fluorine
- R represents a radical selected from the group of:
- R 8 and R 9 independently of one another are hydrogen, (dC 8 ) alkyl, optionally substituted by (dC 4 ) alkyl (C 3 -C 6 ) cycloalkyl, optionally substituted by halogen, phenyl or 5- or 6-membered heteroaryl
- R 8 and R 9 together with the nitrogen atom to which they are attached form a morpholine, piperazine, piperidine or pyrrolidine ring, where the rings in turn can be substituted by (dC 4 ) alkyl, (C6-do) aryl, 5- or 6-membered heteroaryl, 5- or 6-membered heterocyclyl bonded via a carbon atom,
- aryl, heteroaryl and heterocyclyl in turn are substituted by halogen, cyano, nitro, carboxyl, amino, trifluoromethyl, optionally substituted by hydroxy (dC 4 ) -alkyl, (dC 4 ) - alkoxy, (dC 4 ) - alkylamino, (dC 4 ) - Alkanoyl, (dC ⁇ -alkoxycarbonyl, (dC 4 ) -alkanoylamino, (dC) -alkoxycarbonylamino or 6-membered heterocyclyl may be substituted,
- R 10 and R 11 independently of one another for hydrogen, (dC 6 ) - alkyl
- alkyl and cycloalkyl for their part can be substituted by hydroxy, (-CC 4 ) alkoxy, phenyl, 5- or 6-membered heteroaryl or NR 15 R 16 ,
- R 15 and R 16 independently of one another for hydrogen
- R 15 and R 16 together with the nitrogen atom to which they are attached form a morpholine, piperazine, piperidine or pyrrolidine ring, the rings in turn being able to be substituted by (dC 4 ) alkyl,
- Phenyl and heteroaryl in turn by fluorine, chlorine, hydroxy, amino, cyano, trifluoromethyl, (dC 4 ) alkyl, (C ⁇ -C 4 ) -
- R 10 and R 11 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycle, which may contain a further hetero atom O or N in the ring and which is fluorine, hydroxyl, carboxyl, 5- to 7 membered heterocyclicl, which may contain one or two further heteroatoms N and / or O in the ring, which in turn may be substituted by (dC 4 ) - alkyl or (dC) - alkoxy carbonyl, (dC 4 ) - alkoxy, if appropriate substituted by hydroxy, (dC 4 ) -alkoxy or NR 17 R 18- substituted (CC 4 ) -alkyl, (CC 4 ) -alkanoyl, (Ci-C) -alkoxycarbonyl or NR 12 R 13 ,
- R 12 and R 13 independently of one another represent hydrogen or (Ci-C) -alkyl or
- R 12 and R 13 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further hetero atom O or N in the ring and which is substituted by (dC 6 ) - alkyl, (dC 6 ) - Alkanoyl or (C 1 -C 6 ) alkoxycarbonyl may be substituted,
- R 17 and R 18 are independently hydrogen, optionally substituted by hydroxy (dC 4 ) alkyl or phenyl
- R 17 and R 18 together with the nitrogen atom to which they are attached form a pyrrolidine ring
- R 10 and R 11 together with the nitrogen atom to which they are attached form a 7- to 12-membered bicyclic or tricyclic heterocycle which is fused or spirocyclic and one or two further heteroatoms from the series N and / or O in the ring and which can be substituted by (C 3 -C 4 ) alkyl, (-C-C 4 ) alkoxycarbonyl, (dC) alkanoyl or benzyl,
- alkylamino in turn can be substituted by a 5- or 6-membered heterocyclyl
- R > 6 D represents hydrogen or methyl
- R and R independently of one another denote hydrogen, fluorine or chlorine
- R 3 and R 4 are hydrogen
- R represents a radical selected from the group of:
- alkyl and alkoxy in turn by hydroxy, carboxyl, (dC 4 ) - alkoxy, methyloxycarbonyl, ethyloxycarbonyl, NR 8 R 9 , or
- R 8 and R 9 independently of one another for hydrogen, (dC 8 ) -
- R 8 and R 9 together with the nitrogen atom to which they are attached form a piperidine, 2-methylpiperidine or 2,6-dimethylpiperidine ring,
- Piperidin-3-yl, piperidin-4-yl and pyrrolidin-2-yl can in turn be substituted by methyl, ethyl, n-propyl, isopropyl, methylcarbonyl or ethylcarbonyl,
- R 10 and R 11 independently of one another represent hydrogen, (dC) - alkyl, 3-hydroxypropyl, 2-hydroxycyclohexyl, 2-aminocyclohexyl, phenyl, pyridyl or pyrazolyl,
- R 10 and R 11 together with the nitrogen atom to which they are attached are a piperazine, 3-methylpiperazine, 3,5-dimethylpiperazine, 4-isobutylpiperazine, morpholine, pyrrolidine, 3-aminopyrrolidine, 3-memylaminopyrrolidine, 3- (N, N-dimethylamino) pyrrolidine, 2-aminomethylpyrrolidine, 3-hydroxypyrrolidine, 2-hydroxymethylpyrrolidine or 2-
- R 14 represents methoxy, piperidinyl-N-ethylamino, piperidinyl or piperazinyl,
- R represents hydrogen or methyl
- Ner compounds of the formula (I) in which R 1 is fluorine are also particularly preferred.
- the present invention relates to compounds of the formula (I)
- X represents ⁇ or C-H
- Y represents ⁇ -R 7 , O or S
- R 7 represents hydrogen, benzyl, phenyl, (CC 6 ) alkyl or (C 3 -C 8 ) cycloalkyl,
- alkyl and cycloalkyl in turn can be substituted by fluorine, hydroxyl, amino, carboxyl, (-C-C 6 ) alkoxy, (dC 6 ) -alkylamino or morpholinyl,
- R 6 represents hydrogen, halogen, trifluoromethyl, (dC ⁇ -alkylamino or WR 7 ,
- W represents NH, O or a bond
- R 1 and R 2 independently of one another denote hydrogen, halogen or cyano
- R and R 4 independently of one another denote hydrogen, fluorine or chlorine
- R 5 represents a radical which is selected from the group of:
- Alkoxy, (C6-C ⁇ o) aryl or NR 8 R 9 may be substituted
- R 8 and R 9 independently of one another represent hydrogen, (dC 6 ) -alkyl or 5- to 10-membered heteroaryl or R and R together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further heteroatom O or N in the ring and which is (C 1 -C 6 ) -alkyl, (C 1 -C 6 ) alkanoyl or (dC 6 ) alkoxycarbonyl may be substituted,
- aryl, aryloxy, heteroaryl and heteroaryloxy in turn by halogen, nitro, carboxyl, amino, trifluoromethyl, (C ⁇ -Ce) alkyl, (dC 6 ) alkoxy, (dC 6 ) alkylamino, (dC 6 ) alkanoyl, ( dC 6 ) - alkoxycarbonyl, (dC 6 ) -alkanoylamino or (-C-C 6 ) alkoxycarbonylamino can be substituted,
- R 10 and R 11 independently of one another represent hydrogen, (dC 6 ) alkyl, (C 3 -C 8 ) cycloalkyl, (C 6 -do) aryl or 5- to 10-membered heteroaryl,
- NR 8 R 9 can be substituted
- R 8 and R 9 have the meaning given above and
- Aryl and heteroaryl in turn can be substituted by fluorine, chlorine, amino, trifluoromethyl, (dC 6 ) -alkyl (dC 6 ) - alkylamino or (C ⁇ -C 6 ) - alkanoylamino,
- R 10 and R 11 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle, which by fluorine, carboxyl, 1,1-dioxyethylene, 5- or 6-membered heterocyclyl with one or two Heteroatoms N and or O, which in turn can be substituted by (dC 4 ) alkyl, (dC 4 ) alkoxy, by hydroxy or (dC 4 ) alkoxy substituted (dC 4 ) alkyl, (dC 4 ) alkanoyl or NR 12 R 13 is substituted,
- R 12 and R 13 independently of one another denote hydrogen, (dC 6 ) alkyl, (dC ⁇ -alkoxycarbonyl, (C 3 -C 8 ) cycloalkyl or (dC 4 ) alkanoyl
- R 12 and R 13 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain another hetero atom O or N in the ring and which is represented by (dC 6 ) -alkyl, (dC 6 ) - Alkanoyl or (-CC 6 ) alkoxycarbonyl may be substituted, or
- R 10 and R 11 together with the nitrogen atom to which they are attached form a 7- to 12-membered bicyclic heterocycle which is fused or spirocyclic and can have one or two further heteroatoms from the series N and / or O in the ring and by fluorine, (dC 4 ) alkyl, (C ⁇ -C 4 ) -
- alkoxycarbonyl, (C 1 -C) -alkanoyl or benzyl may be substituted
- R 6 represents hydrogen, (CC 4 ) - alkyl, hydroxy, fluorine, chlorine or NH-R 7 ,
- R 7 represents hydrogen or (dC 4 ) - alkyl, which can be substituted by fluorine, hydroxy, methoxy, (dC 4 ) - alkylamino or morpholinyl
- R 1 and R 2 independently of one another denote hydrogen, fluorine or chlorine
- R 3 and R 4 are hydrogen
- R 5 represents a radical which is selected from the group of:
- R 8 and R 9 independently of one another represent hydrogen, (dC) -alkyl or 5- or 6-membered heteroaryl or
- R 8 and R 9 together with the nitrogen atom to which they are attached form a morpholine, piperazine or N-methylpiperazine ring,
- aryl, aryloxy, heteroaryl and heteroaryloxy in turn by fluorine, chlorine, nitro, carboxyl, amino, trifluoromethyl, (dC 4 ) - alkyl, (dC) -alkoxy, (dC) -alkylamino, (C ⁇ -C 4 ) alkoxycarbonyl, (dC 4 ) -AJkanoylamino or (dC 4 ) -alkoxycarbonylamino may be substituted,
- R 10 and R ⁇ independently of one another are hydrogen, (CrC 6 ) alkyl, (C 3 -C 3 ) cycloalkyl, (C 6 -C 10 ) aryl or 5- to 10-membered heteroaryl, where alkyl and cycloalkyl for their part by hydroxyl, (C ⁇ -C6) - alkoxy, (C 6 -C 10) -aryl, 5- to 10-membered heteroaryl, or NR 8 R 9 may be substituted
- R 8 and R 9 have the meaning given above
- Aryl and heteroaryl may in turn be substituted by fluorine, chlorine, amino, trifluoromethyl, (dC 6 ) -alkyl (dC 6 ) -alkylamino or (d-C 6 ) - alkanoylamino
- R 10 and R 11 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle, which is characterized by fluorine, carboxyl, 1,1-dioxyethylene, 5- or 6-membered heterocyclyl having one or two heteroatoms N and / or
- R 12 and R 13 independently of one another are hydrogen, (dC 6 ) - alkyl, (dC 4 ) -alkox ⁇ carbonyl, (C 3 -C 8 ) -cycloalkyl or (C ! -C) -alkanoyl or
- R : 2 and R 13 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle which may contain a further hetero atom O or N in the ring and which is represented by (dC 6 ) -alkyl, (i.e. -C ⁇ ) - Alkanoyl or (dC ⁇ alkoxycarbonyl may be substituted, or
- R 10 and R 11 together with the nitrogen atom to which they are attached form a 7- to 12-membered bicyclic heterocycle which is fused or spirocyclic and can have one or two further heteroatoms from the series N and / or O in the ring and which can be substituted by fluorine, (dC 4 ) - alkyl, (dC) - alkoxycarbonyl, (dG ⁇ -alkanoyl or benzyl,
- R 6 represents hydrogen or amino
- R and R independently of one another denote hydrogen, fluorine or chlorine
- R > 3 “and”, R is hydrogen
- R 5 represents a radical which is selected from the group of:
- alkyl. and alkoxy can in turn be substituted by amino or morpholinyl
- phenyl, phenoxy, pyridyl and pyridyloxy in turn can be substituted by fluorine, chlorine, amino, methyl or NH-CO-CH 3 ,
- worm R 10 and R 11 independently of one another represent hydrogen, 2-hydroxyethyl, 3-hydroxypropyl, 2-aminoethyl, 3-aminopropyl, 2-morpholinoethyl, 3-morpholinopropyl, 2-aminocyclohexyl, pyridyl or aminopyridyl
- R 10 and R 11 together with the nitrogen atom to which they are attached, a piperazine, N-methylpiperazine or N-isopropylpiperazine ring or a radical
- the present invention furthermore relates to a process for the preparation of the compounds of the formula (I), which is characterized in that either [A] Compounds of Formula (11)
- R 5 has the meaning given above
- R 1 , R 2 , R 3 and R 4 have the meaning given above,
- reaction step [A] if X 1 is hydrogen, the reaction takes place, optionally in the presence of a base, either in inert solvents at atmospheric pressure in a temperature range from 20 ° C. to the reflux of the solvents or at elevated pressure in the autoclave at temperatures above the boiling point of the solvent up to 250 ° C or alternatively in bulk in the melt.
- a base either in inert solvents at atmospheric pressure in a temperature range from 20 ° C. to the reflux of the solvents or at elevated pressure in the autoclave at temperatures above the boiling point of the solvent up to 250 ° C or alternatively in bulk in the melt.
- Inert solvents are, for example, alcohols such as methanol, ethanol, propanol, isopropanol, butanol or 2-ethylhexanol, N-alkylated carboxamides such as dimethylformamide, dimethylacetamide or ⁇ -methylpyrrolidone, alkyl sulfoxides such as dimethyl sulfoxide, or other solvents such as acetonitrile or pyridine. Ethanol, butanol, 2-ethylhexanol, ⁇ -methylpyrrolidone or dimethylformamide are preferred.
- Bases are, for example, alkali metal hydroxides such as sodium or potassium hydroxide, or alkali metal alcoholates such as sodium or potassium tert-butoxide, or alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, or amides such as lithium diisopropylamide, or other bases such as DBU, triethylamine or diisopropylefhylamine, preferably diisopropylethylamine or triethylamine.
- alkali metal hydroxides such as sodium or potassium hydroxide
- alkali metal alcoholates such as sodium or potassium tert-butoxide
- alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate
- amides such as lithium diisopropylamide
- other bases such as DBU, triethylamine or diisopropylefhylamine, preferably diisopropylethylamine or triethylamine.
- Inert solvents are, for example, ethers such as dioxane, tetrahydrofuran or
- 1,2-dimethoxyethane hydrocarbons such as benzene, xylene or toluene, nitroaromatics such as nitrobenzene, optionally N-alkylated carboxamides such as dimethylformamide, dimethylacetamide, alkyl sulfoxides such as dimethyl sulfoxide or cyclic lactams such as N-methylpyrrolidone.
- the solvents may be used with the addition of ethanol or water. Preferred solvents are
- Palladium (O) or palladium ( ⁇ l) compounds in particular bis (diphenylphosphanferrocenyl) palladium ( ⁇ ) chloride, dichlorobis (triphenylphosphine) palladium or tetrakis (triphenylphosphine) palladium (O), are preferably used as transition metal catalysts.
- Sodium or potassium tert-butoxide, or alkali metal hydroxides or salts such as potassium acetate, sodium hydroxide, sodium hydrogen carbonate, sodium carbonate or potassium carbonate, optionally in the form of their aqueous solutions, are preferred as bases.
- process step [B] the conversion to compounds of the formula (I) takes place in aqueous hydrochloric acid solution, preferably in a temperature range from 70 ° C. to 110 ° C. at normal pressure.
- R 5 has the meaning given above, in phosphoryl chloride with addition of 0.01 to one equivalent of dimethylformamide or N, N-dimethylaniline or N, N-diethylaniline, preferably in a temperature range from 50 ° C. to the reflux temperature of the solvent at normal pressure.
- R 5 has the meaning given above and
- X 2 represents alkyl, preferably methyl or ethyl
- the compounds of the formulas (NDI) and (TX) are reacted, for example, in two stages initially with concentrated hydrochloric acid in ethanol, preferably in one Temperature range from 50 ° C to the reflux of the solvents at normal pressure, and then with aqueous sodium hydroxide solution, preferably in a temperature range from 50 ° C to the reflux of the solvents at normal pressure.
- R 1 , R 2 , R 3 and R 4 have the meaning given above,
- X 3 represents halogen, preferably fluorine or chlorine
- X 3 can represent a nitro group.
- the reaction is preferably carried out in bulk in the presence of potassium hydroxide as the base in the melt at a temperature of 200 ° C. to 280 ° C. or in an inert solvent such as N, N-dimethylformamide, N-methylpyrrolidone or nitrobenzene in the presence of a base such as potassium hydroxide, potassium tert-butoxide or sodium hydride at a temperature of 120 ° C to 280 ° C.
- Neritatien of formula (N) can be prepared by Neritatien of formula (XU),
- R 1 , R 2 , R 3 and R 4 have the meaning given above,
- the reaction is generally carried out in inert solvents, preferably in a temperature range from room temperature to the reflux of the solvents at atmospheric pressure to 3 bar.
- Reducing agents are, for example, palladium on activated carbon and hydrogen, platinum oxide on activated carbon and hydrogen, tin dichloride or titanium trichloride; preference is given to palladium on activated carbon and hydrogen in the presence of hydrazine hydrate or platinum oxide on activated carbon and hydrogen.
- Inert solvents are, for example, ethers such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or di- ethylene glycol dimethyl ether, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol or 2-ethylhexanol, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, or other solvents such as dimethylformamide, dimethylacetamide , Acetonitrile or pyridine, preferred solvents are ethanol, n-butanol or 2-ethylhexanol.
- ethers such as diethyl ether, methyl tert-butyl ether, 1,2-dime
- X represents halogen, preferably fluorine or chlorine
- reaction is generally carried out in inert solvents, if appropriate in the presence of a base, preferably in a temperature range from room temperature to the reflux of the solvents at atmospheric pressure.
- Inert solvents are, for example, halogenated hydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane, ethers such as dioxane, tetrahydrofuran or 1,2-dimethoxyefane, or other solvents such as acetone, dimethylformamide, dimethylacetamide, 2-butanone or acetonitrile, preferably acetonitrile, dimethylformamide or 1,2-dimethoxyethane.
- halogenated hydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane
- ethers such as dioxane, tetrahydrofuran or 1,2-dimethoxyefane
- other solvents such as acetone, dimethylformamide, dimethylacetamide, 2-butanone or acetonitrile, preferably acetonitrile, dimethylformamide or 1,2-dimethoxyethane.
- Bases are, for example, alkali carbonates such as cesium carbonate, sodium or potassium carbonate, or sodium or potassium methoxide, or sodium or potassium ethoxide or potassium tert-butoxide, or ide such as sodium amide, lithium bis (trimethylsilyl) amide or lithium diisopropylamide, or organometallic Compound such as butyllithium or phenyllithium, or other bases such as sodium hydride,
- DBU preferably potassium tert-butoxide, cesium carbonate, potassium carbonate or sodium carbonate.
- the compounds of formula (I) can be further derivatized, for example, by reaction with oxidizing agents.
- the compounds according to the invention show an unforeseeable, valuable pharmacological and pharmacokinetic spectrum of action.
- the pharmaceutical activity of the compounds according to the invention can be explained by their action as Rho-kinase inhibitors.
- the present invention furthermore relates to the use of the compounds according to the invention for the treatment and or prophylaxis of diseases, preferably cardiovascular diseases.
- the compounds according to the invention are suitable for prophylaxis and / or
- cardiovascular diseases such as high blood pressure and heart failure, stable and unstable angina pectoris, peripheral and cardiac vascular diseases.
- Arrhythmias, thromboembolic disorders and ischemia such as myocardial infarction, stroke, transient and ischemic attacks, peripheral circulatory disorders, subarachnoid hemorrhage, prevention of
- Restenoses such as after thrombolysis therapies, percutaneous franslurninal angioplasties (PTA), percutaneous transluminal coronary angioplasties (PTCA), bypass and for the prophylaxis and / or treatment of arteriosclerosis, asthmatic diseases, COPD and diseases of the genitourinary system such as female prostate hypertrophy, erectile dysfunction, prostate hypertrophy
- the compounds according to the invention can be used for the prophylaxis and / or treatment of cancer diseases, in particular tumors.
- tumors includes both benign and malignant tumors and thus, for example, also benign neoplasias, dysplasias, hyperplasias, and also neoplasias with metastasis formation.
- Other examples of tumors are carcinomas, sarcomas, carcinosarcomas, tumors of the hematopoietic organs, tumors of the nerve tissue e.g. of the brain or
- Tumors from skin cells Tumor formation leads to uncontrolled or insufficiently controlled cell division.
- the tumor can be localized, but it can also infiltrate the surrounding tissue and then settle in a new location through the lymphatic system or through the bloodstream.
- Primary tumors originated in the organ in which they are found. Secondary tumors have spread through Metastasis formation in another organ and then spread to its new location.
- the present invention furthermore relates to the use of the compounds according to the invention for the prophylaxis and / or treatment of diseases, in particular the previously mentioned clinical pictures.
- the present invention furthermore relates to the use of the compounds according to the invention for the production of a medicament for the prophylaxis and / or treatment of diseases, in particular the aforementioned clinical pictures.
- the present invention furthermore relates to a method for the prophylaxis and / or treatment of diseases, in particular the aforementioned diseases, using a cardiovascularly effective amount of the compound according to the invention.
- the present invention furthermore relates to medicaments containing a compound according to the invention and one or more further active substances, in particular for the prophylaxis and / or treatment of the aforementioned diseases.
- the compound according to the invention can act systemically and or locally.
- it can be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, transdermal, conjunctival, otic, as stents or as an implant.
- the compound according to the invention can be administered in suitable application forms.
- state-of-the-art, fast and / or modified application forms which release the compounds according to the invention and which crystallize and / or the compounds according to the invention are suitable Contain amorphized and / or dissolved form, such as tablets (non-coated or coated tablets, for example with enteric-coated, delayed dissolving or insoluble coatings that control the release of the compounds according to the invention), rapidly disintegrating tablets or films / wafers, capsules in the oral cavity, Dragees, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
- Parenteral administration can be done by bypassing a resorption step (intravenous, intraarterial, intracardial, intraspinal or intralumbal) or by switching on absorption (intramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal).
- Suitable forms of application for parenteral administration include: Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates and sterile powders.
- Inhalation drug forms e.g.
- the compounds according to the invention can be converted into the administration forms mentioned in a manner known per se. This is done using inert, non-toxic, pharmaceutically suitable excipients. These include carriers (e.g. microcrystalline cellulose), solvents (e.g. liquid polyethylene glycols), emulsifiers (e.g. sodium dodecyl sulfate), dispersants (e.g. polyvinylpyrrolidone), synthetic and natural biopolymers (e.g. albumin), stabilizers (e.g. antioxidants such as ascorbic acid), Colorants (eg inorganic pigments such as iron oxides) or taste and / or smell correctives.
- the present invention further relates to medicaments which contain at least one compound according to the invention, preferably together with one or more inert non-toxic, pharmaceutically suitable excipients, and to their use for the purposes mentioned above.
- a single dose contains the compound according to the invention preferably in amounts of about 0.1 to about 80, in particular 0.1 to 30 mg / kg body weight.
- Device type MS Micromass ZQ
- Device type HPLC Waters Alliance 2790
- Pillar Pillar
- Device type MS Micromass ZQ
- Device type HPLC HP 1100 Series
- UV DAD Column: Grom-Sil 120 ODS-4 HE 50 mm x 2 mm, 3.0 ⁇ m
- Eluent A water + 500 ⁇ l 50% formic acid / 1
- eluent B acetonitrile + 500 ⁇ l 50% formic acid / 1
- Oven 50 ° C, flow: 0.8 ml / min, UV detection: 210 nm.
- Method 12 fLC / MS
- Instrument Micromass Platform LCZ with HPLC Agilent Series 1100; Column: Grom-SD 120 ODS-4 HE, 50 mm x 2.0 mm, 3 ⁇ m; Eluent A: 1 1 water + 1 ml 50% formic acid, eluent B: 1 1 acetonitrile + 1 ml 50% formic acid; Gradient: 0.0 min 100% A - 0.2 min 100% A - »2.9 min 30% A -» 3.1 min 10% A - »4.5 min 10% A; Oven: 55 ° C, flow: 0.8 ml / min, UV detection: 210 nm.
- Method 13 (LC / MS
- Device type MS Micromass ZQ
- Device type HPLC HP 1100 Series
- UV DAD Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20 mm x 4 mm
- Eluent A 1 1 water + 0.5 ml 50% formic acid
- eluent B 1 1 acetonitrile + 0.5 ml 50% formic acid
- Device type MS Micromass ZQ
- Device type HPLC Waters Alliance 2795; Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20 mm x 4 mm; Eluent A: 1 1 water + 0.5 ml 50% formic acid, eluent B: 1 1 acetonitrile + 0.5 ml 50% formic acid; Gradient: 0.0 min 90% A flow 1 ml min - »2.5 min 30% A flow 2 ml / min - 3.0 min 5% A flow 2 ml / min • » 4.5 min 5% A flow 2 ml / min; Oven: 50 ° C; UV detection: 210 nm.
- Device type MS Micromass ZQ
- Device p HPLC Waters Alliance 2795; Column: Merck Chromolith SpeedROD RP-18e 50 mm x 4.6 mm; Eluent A: water + 500 ⁇ l 50% formic acid / 1; Eluent B: acetonitrile + 500 ⁇ l 50% formic acid / 1; Gradient: 0.0 min 10% B - »3.0 min 95% B - 4.0 min 95% B; Oven: 35 ° C; Flow: 0.0 min 1.0 ml / min, 3.0 min 3.0 ml / min, 4.0 min 3.0 ml / min; UV detection: 210 nm. Method 17 (LC / MS)
- the crystals that precipitate are filtered off and washed with water.
- 6-aminoindazole 8.00 g (60.1 mmol) 6-aminoindazole are mixed with dilute sulfuric acid (8 ml concentrated sulfuric acid in 52.8 ml H 2 O) and cooled to 0 ° C. An aqueous sodium nitrite solution (4.48 g sodium nitrite in 12.8 ml water) is slowly added dropwise. The mixture is stirred at 0 ° C for 1 hour. After adding 5.60 g (90.6 mmol) of boric acid and a further 8 ml of dilute sulfuric acid
- Potassium carbonate and allowed to stir at 40 ° C overnight. For working up, it is suctioned off through diatomaceous earth, diluted with water and extracted three times with ethyl acetate; The combined organic phases are washed once with saturated aqueous sodium chloride solution, dried over sodium sulfate and concentrated on a rotary evaporator. The residue is washed twice over silica gel with cyclohexane / ethyl acetate
- the filtrate is evaporated to dryness on a rotary evaporator.
- the residue is diluted with 50 ml of water and the solution made alkaline with 45% sodium hydroxide solution. Then dichloromethane is added and the mixture is suctioned off through diatomaceous earth.
- the filtrate is six times with 100 ml dichloromethane extra value, the organic phase is dried over sodium sulfate and evaporated to dryness on a rotary evaporator.
- the residue is dried in a high vacuum. For further purification, it is triturated with tetrahydrofuran and the solid is filtered off with suction.
- the filtrate is concentrated, the residue is taken up in dichloromethane, dried and concentrated. Yield: 3.5 g (78%)
- Example XV ⁇ i The previously described compound (example XV ⁇ i) can alternatively also be produced by the following process: Example XVIII (Alternative Manufacturing Method)
- connection described above can alternatively also be produced using the following method:
- Dodecene-containing residue is mixed with petroleum ether and cooled in an ice bath.
- Example XIX Analogously to Example XIX (alternative method), the title compound is catalyzed by hydrogenation of 408 mg (1.38 mmol) ⁇ 4 - [(6-chloro-1H-pyrrolo [2,3-b] pyridine-
- Example XV Analogously to Example XV, the title compound is oxidized by 11 g (54.1 mmol) of 3-methyl-1H-pyrrolo [2,3-b] pyridine (Hands, D .; Bishop, B .; Cameron, M .;
- Example XVflT Analogously to Example XV, the title compound is oxidized with 898 mg (5.39 mmol) of 4-chloro-3-methyl-1 H-pyrrolo [2,3-b] pyridine (from Example XXXVflT)
- Example XXX Analogously to Example XXX, the title compound is made from 688 mg (3.77 mmol) of 4-chloro
- Example LEI The title compound is synthesized analogously to Example LEI from 2.3 g (8.76 mmol) of 4- (4-amino-2-chl ⁇ henoxy) -2-fluorobenzonitrile (from Example LLT) and hydrazine hydrate.
- the reaction mixture is diluted with dichloromethane (50 ml), it is washed successively with water (20 ml), 1N hydrochloric acid (30 ml), saturated aqueous sodium hydrogen carbonate solution (30 ml) and saturated aqueous sodium chloride solution.
- the organic phase is dried over anhydrous magnesium sulfate.
- the solution is concentrated in vacuo.
- the residue (1.2 g) is dissolved in 30 ml of ethanol and mixed with 0.13 ml (0.61 mmol) of 37% hydrochloric acid and stirred under reflux for one hour.
- reaction solution is cooled to 0 ° C. and carefully dripped onto ice water (150 ml).
- the aqueous suspension is neutralized with a 45% sodium hydroxide solution and extracted three times with ethyl acetate (70 ml each).
- the organic phase is dried over anhydrous magnesium sulfate and concentrated.
- Example XXLX synthesized. After cleaning by means of preparative HPLC, the product is obtained.
- Example 25 Analogously to Example 25, the title compound is obtained from 35 mg (0.14 mmol) of [4- (2,3-dihydro-lH-pyrrolo [2,3-b] pyridin-4-yloxy) -3-fluoropheneyl] amine (from Example XLNI ) and 39 mg (0.15 mmol) of 4-CMor-6- (4-fluq ⁇ henyl) pyrimidm-2-amine (from Example LIX). After cleaning by means of preparative HPLC, the product is obtained.
- Example XLX 0.209 g (1.12 mmol) of methyl 2-amino-6-chloropyrimidine-4-carboxylate (manufactured according to G. Doyle Daves, Fred Baiocchi, Roland K. Robins, and CC Cheng, J Org. Chem., 26 (1961), 2755-2763) and 0.4 g (1.12 mmol) [3 -Fluoro-4- (l H-pyrrolo [2,3-b] pyrichn-4-ylo ⁇ y) phenyl] amine (Example XLX) are in 5 ml of water and 5 ml of ethanol suspended. 0.11 ml (1.34 mmol) of 37% hydrochloric acid are added. The mixture is stirred at 100 ° C for 18 hours. After cooling, it is neutralized with an aqueous saturated sodium hydrogen carbonate solution. The resulting precipitate is filtered off and dried. 0.46 g of product (68% of theory) is obtained.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005501803A JP4681451B2 (ja) | 2002-10-28 | 2003-10-16 | Rho−キナーゼ阻害剤としてのヘテロアリールオキシ置換フェニルアミノピリミジン類 |
AU2003278088A AU2003278088A1 (en) | 2002-10-28 | 2003-10-16 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
DE50304983T DE50304983D1 (de) | 2002-10-28 | 2003-10-16 | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
CA2503646A CA2503646C (en) | 2002-10-28 | 2003-10-16 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
EP03769398A EP1562935B1 (de) | 2002-10-28 | 2003-10-16 | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
US10/531,889 US7737153B2 (en) | 2002-10-28 | 2003-10-16 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10250113.0 | 2002-10-28 | ||
DE10250113 | 2002-10-28 | ||
DE10332232.9 | 2003-07-16 | ||
DE10332232A DE10332232A1 (de) | 2002-10-28 | 2003-07-16 | Heteroaryloxy-substituierte Phenylaminopyrimidine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004039796A1 true WO2004039796A1 (de) | 2004-05-13 |
Family
ID=32231863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/011452 WO2004039796A1 (de) | 2002-10-28 | 2003-10-16 | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
Country Status (8)
Country | Link |
---|---|
US (1) | US7737153B2 (de) |
EP (1) | EP1562935B1 (de) |
JP (1) | JP4681451B2 (de) |
AU (1) | AU2003278088A1 (de) |
CA (1) | CA2503646C (de) |
DE (1) | DE50304983D1 (de) |
ES (1) | ES2273047T3 (de) |
WO (1) | WO2004039796A1 (de) |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097790A1 (de) * | 2004-04-08 | 2005-10-20 | Bayer Healthcare Ag | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer |
EP1606283A2 (de) * | 2003-03-03 | 2005-12-21 | Array Biopharma, Inc. | P38 inhibitor und anwendungsverfahren dafür |
WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
WO2006110763A1 (en) * | 2005-04-08 | 2006-10-19 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives and their use for the treatment of cancer |
WO2006110447A2 (en) * | 2005-04-08 | 2006-10-19 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives and their use in the treatment of cancer |
WO2006123165A2 (en) * | 2005-05-19 | 2006-11-23 | Astex Therapeutics Limited | Pyrimidine derivatives as hsp90 inhibitors |
JP2008502610A (ja) * | 2004-06-15 | 2008-01-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 3−アミノインダゾール |
WO2008079294A1 (en) * | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
US7528146B2 (en) | 2004-12-15 | 2009-05-05 | Lanxess Deutschland Gmbh | Substituted 1H-pyrrolo[2,3-b]pyridines and preparation thereof |
US7678804B2 (en) | 2003-10-10 | 2010-03-16 | Bayer Healthcare Llc | Pyrimidine derivatives for treatment of hyperproliferative disorders |
US7687522B2 (en) | 2006-12-20 | 2010-03-30 | Amgen Inc. | Substituted pyridines and pyrimidines and their use in treatment of cancer |
US7723347B2 (en) | 2004-04-27 | 2010-05-25 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenylamino-pyrimidines |
AU2006304879B2 (en) * | 2005-10-21 | 2010-06-10 | Amgen Inc. | Pyrrolo-pyridine derivatives for the treatment of cancer diseases |
WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
AU2006327876B2 (en) * | 2005-12-20 | 2010-12-16 | Ziarco Inc. | Pyrimidine derivatives |
WO2011047300A1 (en) | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
WO2011076878A1 (en) * | 2009-12-23 | 2011-06-30 | Palau Pharma, S.A. | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
US8039639B2 (en) | 2006-01-31 | 2011-10-18 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US8193193B2 (en) | 2005-07-12 | 2012-06-05 | Kowa Co., Ltd. | Agent for prevention or treatment of glaucoma |
WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
US8501735B2 (en) | 2009-10-29 | 2013-08-06 | Palau Pharma, S.A. | N-containing heteroaryl derivatives as JAK3 kinase inhibitors |
US8518983B2 (en) | 2003-03-03 | 2013-08-27 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
WO2013137491A1 (ja) | 2012-03-15 | 2013-09-19 | 国立大学法人京都大学 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
WO2013151186A1 (ja) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | エリスロポエチン産生細胞の誘導方法 |
US8629161B2 (en) | 2005-06-21 | 2014-01-14 | Kowa Co., Ltd. | Preventive or remedy for glaucoma |
WO2014165663A1 (en) | 2013-04-03 | 2014-10-09 | Cellular Dynamics International, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
WO2014168264A1 (ja) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
WO2014200115A1 (ja) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | 腎前駆細胞の製造方法及び腎前駆細胞を含む医薬 |
US8921376B2 (en) | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
WO2015020113A1 (ja) | 2013-08-07 | 2015-02-12 | 国立大学法人京都大学 | 膵ホルモン産生細胞の製造法 |
WO2015034012A1 (ja) | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | 新規ドーパミン産生神経前駆細胞の誘導方法 |
WO2015143342A1 (en) | 2014-03-21 | 2015-09-24 | Cellular Dynamics International, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
WO2015200920A1 (en) | 2014-06-27 | 2015-12-30 | The Regents Of The University Of California | Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof |
CN105693522A (zh) * | 2016-03-10 | 2016-06-22 | 中国农业科学院上海兽医研究所 | 一种对硝基邻甲酚的制备方法 |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
US9505784B2 (en) | 2009-06-12 | 2016-11-29 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
WO2017075389A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2017183736A1 (ja) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | ドーパミン産生神経前駆細胞の製造方法 |
EP3255142A1 (de) | 2009-10-19 | 2017-12-13 | Cellular Dynamics International, Inc. | Herstellung von kardiomyozyten |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
US9988604B2 (en) | 2009-04-22 | 2018-06-05 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
WO2018115383A1 (en) | 2016-12-21 | 2018-06-28 | Chiesi Farmaceutici S.P.A. | Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors |
WO2018122775A1 (en) * | 2016-12-29 | 2018-07-05 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2018138293A1 (en) | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2018216743A1 (ja) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法 |
WO2019048479A1 (en) | 2017-09-07 | 2019-03-14 | Chiesi Farmaceutici S.P.A. | DERIVATIVES OF TYROSINE ANALOGS AS INHIBITORS OF RHO-KINASE |
WO2019092939A1 (ja) | 2017-11-10 | 2019-05-16 | 株式会社リジェネシスサイエンス | 培養細胞の製造方法,脊髄損傷疾患の治療剤の製造方法 |
WO2019121406A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Azaindole derivatives as rho-kinase inhibitors |
WO2019121233A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Oxadiazole derivatives as rho-kinase inhibitors |
WO2019121223A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Meta tyrosine derivatives as rho-kinase inhibitors |
WO2019131941A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集抑制剤 |
WO2019131942A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集促進剤 |
WO2019131940A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 多能性幹細胞凝集抑制剤 |
EP3521418A1 (de) | 2013-03-14 | 2019-08-07 | ViaCyte, Inc | Zellkultur |
WO2019160148A1 (ja) | 2018-02-19 | 2019-08-22 | 大日本住友製薬株式会社 | 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 |
US10472610B2 (en) | 2014-05-21 | 2019-11-12 | Kyoto University | Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells |
WO2019238628A1 (en) | 2018-06-13 | 2019-12-19 | Chiesi Farmaceutici S.P.A. | Azaindole derivatives as rho- kinase inhibitors |
WO2020016129A1 (en) | 2018-07-16 | 2020-01-23 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
WO2020022261A1 (ja) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2020084580A1 (en) | 2018-10-26 | 2020-04-30 | Novartis Ag | Methods and compositions for ocular cell therapy |
WO2020130147A1 (ja) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物 |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
WO2020203538A1 (ja) | 2019-03-29 | 2020-10-08 | 株式会社カネカ | 多能性幹細胞を含む細胞集団及びその製造方法 |
WO2020230832A1 (ja) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10906889B2 (en) | 2013-10-18 | 2021-02-02 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2021105908A1 (en) * | 2019-11-25 | 2021-06-03 | Gain Therapeutics Sa | Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase |
US11040957B2 (en) | 2013-10-18 | 2021-06-22 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
US11142507B2 (en) | 2015-09-09 | 2021-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2021220132A1 (en) | 2020-04-27 | 2021-11-04 | Novartis Ag | Methods and compositions for ocular cell therapy |
US11268069B2 (en) | 2014-03-04 | 2022-03-08 | Fate Therapeutics, Inc. | Reprogramming methods and cell culture platforms |
WO2022128851A1 (en) | 2020-12-15 | 2022-06-23 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
WO2022128853A1 (en) | 2020-12-15 | 2022-06-23 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
WO2022128848A1 (en) | 2020-12-15 | 2022-06-23 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho-kinase inhibitors |
WO2022149616A1 (ja) | 2021-01-08 | 2022-07-14 | 国立大学法人京都大学 | ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法 |
US11441126B2 (en) | 2015-10-16 | 2022-09-13 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
WO2022216911A1 (en) | 2021-04-07 | 2022-10-13 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
WO2022259721A1 (ja) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | 間葉系幹細胞の製造方法 |
WO2023017848A1 (ja) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法 |
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2023110700A1 (en) | 2021-12-13 | 2023-06-22 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho-kinase inhibitors |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
CA2690619A1 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
TWI365185B (en) | 2008-07-24 | 2012-06-01 | Lilly Co Eli | Amidophenoxyindazoles useful as inhibitors of c-met |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
JP6076258B2 (ja) | 2010-11-12 | 2017-02-08 | ジョージタウン ユニヴァーシティ | 上皮細胞の不死化および使用法 |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
JP6337124B2 (ja) * | 2013-12-23 | 2018-06-06 | パーデュー、ファーマ、リミテッド、パートナーシップ | インダゾール及びその使用 |
US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
EP3277799B1 (de) | 2015-04-03 | 2020-09-23 | Propagenix Inc. | Ex-vivo-proliferation von epithelzellen |
EP3892718A1 (de) | 2015-09-11 | 2021-10-13 | Propagenix Inc. | Ex-vivo-proliferation von epithelzellen |
US20210189351A1 (en) | 2018-08-20 | 2021-06-24 | Propagenix Inc. | Epithelial cell spheroids |
US20210292766A1 (en) | 2018-08-29 | 2021-09-23 | University Of Massachusetts | Inhibition of Protein Kinases to Treat Friedreich Ataxia |
CN109456224A (zh) * | 2018-12-17 | 2019-03-12 | 鲁东大学 | 一种制备2,6-二氟靛酚乙酸酯的方法 |
CA3235384A1 (en) | 2021-10-18 | 2023-04-27 | Takahiro Ochiya | Compositions and methods of use thereof for treating liver fibrosis |
CA3235862A1 (en) | 2021-10-22 | 2023-04-27 | Takahiro Ochiya | Methods for making extracellular vesicles, and compositions and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
WO2001064654A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | Pyrimidine compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053331A2 (en) * | 2000-01-24 | 2001-07-26 | Adherex Technologies, Inc. | Peptidomimetic modulators of cell adhesion |
DE10226943A1 (de) * | 2002-06-17 | 2004-01-08 | Bayer Ag | Phenylaminopyrimidine und ihre Verwendung |
DE102004017438A1 (de) * | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
-
2003
- 2003-10-16 US US10/531,889 patent/US7737153B2/en not_active Expired - Fee Related
- 2003-10-16 AU AU2003278088A patent/AU2003278088A1/en not_active Abandoned
- 2003-10-16 EP EP03769398A patent/EP1562935B1/de not_active Expired - Fee Related
- 2003-10-16 CA CA2503646A patent/CA2503646C/en not_active Expired - Fee Related
- 2003-10-16 DE DE50304983T patent/DE50304983D1/de not_active Expired - Lifetime
- 2003-10-16 JP JP2005501803A patent/JP4681451B2/ja not_active Expired - Fee Related
- 2003-10-16 WO PCT/EP2003/011452 patent/WO2004039796A1/de active IP Right Grant
- 2003-10-16 ES ES03769398T patent/ES2273047T3/es not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
WO2001064654A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | Pyrimidine compounds |
Non-Patent Citations (1)
Title |
---|
FUKATA YUKO ET AL: "Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells.", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 22, no. 1, January 2001 (2001-01-01), &, pages 32 - 39, XP002267445, ISSN: 0165-6147 * |
Cited By (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1606283A4 (de) * | 2003-03-03 | 2007-05-23 | Array Biopharma Inc | P38 inhibitor und anwendungsverfahren dafür |
EP1606283A2 (de) * | 2003-03-03 | 2005-12-21 | Array Biopharma, Inc. | P38 inhibitor und anwendungsverfahren dafür |
US8518983B2 (en) | 2003-03-03 | 2013-08-27 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
US7678804B2 (en) | 2003-10-10 | 2010-03-16 | Bayer Healthcare Llc | Pyrimidine derivatives for treatment of hyperproliferative disorders |
WO2005097790A1 (de) * | 2004-04-08 | 2005-10-20 | Bayer Healthcare Ag | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer |
US8329716B2 (en) | 2004-04-08 | 2012-12-11 | Bayer Intellectual Property Gmbh | Hetaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors |
US7723347B2 (en) | 2004-04-27 | 2010-05-25 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenylamino-pyrimidines |
WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
JP2008502610A (ja) * | 2004-06-15 | 2008-01-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 3−アミノインダゾール |
US7528146B2 (en) | 2004-12-15 | 2009-05-05 | Lanxess Deutschland Gmbh | Substituted 1H-pyrrolo[2,3-b]pyridines and preparation thereof |
WO2006110763A1 (en) * | 2005-04-08 | 2006-10-19 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives and their use for the treatment of cancer |
WO2006110447A2 (en) * | 2005-04-08 | 2006-10-19 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives and their use in the treatment of cancer |
WO2006110447A3 (en) * | 2005-04-08 | 2007-01-18 | Bayer Pharmaceuticals Corp | Pyrimidine derivatives and their use in the treatment of cancer |
WO2006123165A3 (en) * | 2005-05-19 | 2007-10-11 | Astex Therapeutics Ltd | Pyrimidine derivatives as hsp90 inhibitors |
WO2006123165A2 (en) * | 2005-05-19 | 2006-11-23 | Astex Therapeutics Limited | Pyrimidine derivatives as hsp90 inhibitors |
US8921376B2 (en) | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
US8629161B2 (en) | 2005-06-21 | 2014-01-14 | Kowa Co., Ltd. | Preventive or remedy for glaucoma |
US8193193B2 (en) | 2005-07-12 | 2012-06-05 | Kowa Co., Ltd. | Agent for prevention or treatment of glaucoma |
AU2006304879B2 (en) * | 2005-10-21 | 2010-06-10 | Amgen Inc. | Pyrrolo-pyridine derivatives for the treatment of cancer diseases |
AU2006327876B2 (en) * | 2005-12-20 | 2010-12-16 | Ziarco Inc. | Pyrimidine derivatives |
US7943628B2 (en) * | 2005-12-20 | 2011-05-17 | Pfizer Limited | Pyrimidine derivatives |
US8039639B2 (en) | 2006-01-31 | 2011-10-18 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
US7915287B2 (en) | 2006-12-20 | 2011-03-29 | Amgen Inc. | Substituted heterocycles and methods of use |
US7687522B2 (en) | 2006-12-20 | 2010-03-30 | Amgen Inc. | Substituted pyridines and pyrimidines and their use in treatment of cancer |
WO2008079294A1 (en) * | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
US9988604B2 (en) | 2009-04-22 | 2018-06-05 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
EP3904505A1 (de) | 2009-04-22 | 2021-11-03 | Viacyte, Inc. | Zellzusammensetzungen aus entdifferenzierten neuprogrammierten zellen |
US11905530B2 (en) | 2009-04-22 | 2024-02-20 | Viacyte, Inc. | Cell encapsulation device comprising a pancreatic progenitor cell population |
WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US9505784B2 (en) | 2009-06-12 | 2016-11-29 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
EP4206319A1 (de) | 2009-10-16 | 2023-07-05 | The Scripps Research Institute | Induktion pluripotenter zellen |
WO2011047300A1 (en) | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
EP3235901A1 (de) | 2009-10-16 | 2017-10-25 | The Scripps Research Institute | Induzierung pluripotenter zellen |
EP4364797A2 (de) | 2009-10-19 | 2024-05-08 | FUJIFILM Cellular Dynamics, Inc. | Herstellung von kardiomyozyten |
EP3255142A1 (de) | 2009-10-19 | 2017-12-13 | Cellular Dynamics International, Inc. | Herstellung von kardiomyozyten |
US8946257B2 (en) | 2009-10-29 | 2015-02-03 | Vectura Limited | N-containing heteroaryl derivatives as JAK3 kinase inhibitors |
US8501735B2 (en) | 2009-10-29 | 2013-08-06 | Palau Pharma, S.A. | N-containing heteroaryl derivatives as JAK3 kinase inhibitors |
US8901146B2 (en) | 2009-12-23 | 2014-12-02 | Medicis Pharmaceutical Corporation | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists |
CN102803248B (zh) * | 2009-12-23 | 2015-09-16 | 梅迪奇制药有限公司 | 作为组胺h4受体拮抗剂的氨烷基嘧啶 |
RU2573828C2 (ru) * | 2009-12-23 | 2016-01-27 | Медисиз Фармасьютикал Корпорейшн | Производные аминоалкилпиримидина в качестве антагонистов h4 рецептора гистамина |
WO2011076878A1 (en) * | 2009-12-23 | 2011-06-30 | Palau Pharma, S.A. | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
CN102803248A (zh) * | 2009-12-23 | 2012-11-28 | 帕劳制药股份有限公司 | 作为组胺h4受体拮抗剂的氨烷基嘧啶 |
US9358231B2 (en) | 2009-12-29 | 2016-06-07 | Dana-Farber Cancer Institute, Inc. | Type II RAF kinase inhibitors |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
US11826365B2 (en) | 2009-12-29 | 2023-11-28 | Dana-Farber Cancer Institute, Inc. | Type II raf kinase inhibitors |
US8691574B2 (en) | 2010-06-15 | 2014-04-08 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
EP3382008A1 (de) | 2010-06-15 | 2018-10-03 | FUJIFILM Cellular Dynamics, Inc. | Erzeugung induzierter pluripotenter stammzellen aus kleinen volumina von peripherem blut |
WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US9447382B2 (en) | 2010-06-15 | 2016-09-20 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US10260048B2 (en) | 2010-06-15 | 2019-04-16 | FUJIFILM Cellular Dynamics, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US10844356B2 (en) | 2010-12-22 | 2020-11-24 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
US10144730B2 (en) | 2011-11-17 | 2018-12-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
US10981903B2 (en) | 2011-11-17 | 2021-04-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
WO2013137491A1 (ja) | 2012-03-15 | 2013-09-19 | 国立大学法人京都大学 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
WO2013151186A1 (ja) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | エリスロポエチン産生細胞の誘導方法 |
US10787436B2 (en) | 2012-10-18 | 2020-09-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
EP3521418A1 (de) | 2013-03-14 | 2019-08-07 | ViaCyte, Inc | Zellkultur |
WO2014165663A1 (en) | 2013-04-03 | 2014-10-09 | Cellular Dynamics International, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
WO2014168264A1 (ja) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
WO2014200115A1 (ja) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | 腎前駆細胞の製造方法及び腎前駆細胞を含む医薬 |
WO2015020113A1 (ja) | 2013-08-07 | 2015-02-12 | 国立大学法人京都大学 | 膵ホルモン産生細胞の製造法 |
US9796962B2 (en) | 2013-08-07 | 2017-10-24 | Kyoto University | Method for generating pancreatic hormone-producing cells |
WO2015034012A1 (ja) | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | 新規ドーパミン産生神経前駆細胞の誘導方法 |
US10906889B2 (en) | 2013-10-18 | 2021-02-02 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
US11040957B2 (en) | 2013-10-18 | 2021-06-22 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
US11268069B2 (en) | 2014-03-04 | 2022-03-08 | Fate Therapeutics, Inc. | Reprogramming methods and cell culture platforms |
WO2015143342A1 (en) | 2014-03-21 | 2015-09-24 | Cellular Dynamics International, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
US10472610B2 (en) | 2014-05-21 | 2019-11-12 | Kyoto University | Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells |
WO2015200920A1 (en) | 2014-06-27 | 2015-12-30 | The Regents Of The University Of California | Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof |
US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
US11325910B2 (en) | 2015-03-27 | 2022-05-10 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US11142507B2 (en) | 2015-09-09 | 2021-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
US11441126B2 (en) | 2015-10-16 | 2022-09-13 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
WO2017075389A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
CN105693522A (zh) * | 2016-03-10 | 2016-06-22 | 中国农业科学院上海兽医研究所 | 一种对硝基邻甲酚的制备方法 |
WO2017183736A1 (ja) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | ドーパミン産生神経前駆細胞の製造方法 |
EP4001403A1 (de) | 2016-08-16 | 2022-05-25 | FUJIFILM Cellular Dynamics, Inc. | Verfahren zur differenzierung pluripotenter zellen |
EP4328301A2 (de) | 2016-08-16 | 2024-02-28 | FUJIFILM Cellular Dynamics, Inc. | Verfahren zur differenzierung pluripotenter zellen |
WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
WO2018115383A1 (en) | 2016-12-21 | 2018-06-28 | Chiesi Farmaceutici S.P.A. | Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors |
US11739072B2 (en) | 2016-12-29 | 2023-08-29 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
WO2018122775A1 (en) * | 2016-12-29 | 2018-07-05 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
US11174242B2 (en) | 2016-12-29 | 2021-11-16 | Minoryx Therapeutics S.L. | Heteroaryl compounds and their use |
CN110325516A (zh) * | 2016-12-29 | 2019-10-11 | 米尼奥尔克斯治疗有限公司 | 杂芳基化合物和它们的用途 |
WO2018138293A1 (en) | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
WO2018216743A1 (ja) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法 |
WO2019048479A1 (en) | 2017-09-07 | 2019-03-14 | Chiesi Farmaceutici S.P.A. | DERIVATIVES OF TYROSINE ANALOGS AS INHIBITORS OF RHO-KINASE |
WO2019092939A1 (ja) | 2017-11-10 | 2019-05-16 | 株式会社リジェネシスサイエンス | 培養細胞の製造方法,脊髄損傷疾患の治療剤の製造方法 |
US11725007B2 (en) | 2017-12-18 | 2023-08-15 | Chiesi Farmaceutici S.P.A. | Meta tyrosine derivatives as rho-kinase inhibitors |
WO2019121223A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Meta tyrosine derivatives as rho-kinase inhibitors |
WO2019121233A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Oxadiazole derivatives as rho-kinase inhibitors |
WO2019121406A1 (en) | 2017-12-18 | 2019-06-27 | Chiesi Farmaceutici S.P.A. | Azaindole derivatives as rho-kinase inhibitors |
US11332468B2 (en) | 2017-12-18 | 2022-05-17 | Chiesi Farmaceutici S.P.A. | Azaindole derivatives as Rho-kinase inhibitors |
US11578068B2 (en) | 2017-12-18 | 2023-02-14 | Chiesi Farmaceutici S.P.A. | Oxadiazole derivatives as Rho-Kinase Inhibitors |
WO2019131940A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 多能性幹細胞凝集抑制剤 |
WO2019131941A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集抑制剤 |
WO2019131942A1 (ja) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | 細胞凝集促進剤 |
WO2019160148A1 (ja) | 2018-02-19 | 2019-08-22 | 大日本住友製薬株式会社 | 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 |
WO2019238628A1 (en) | 2018-06-13 | 2019-12-19 | Chiesi Farmaceutici S.P.A. | Azaindole derivatives as rho- kinase inhibitors |
WO2020016129A1 (en) | 2018-07-16 | 2020-01-23 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
WO2020022261A1 (ja) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
WO2020084580A1 (en) | 2018-10-26 | 2020-04-30 | Novartis Ag | Methods and compositions for ocular cell therapy |
WO2020130147A1 (ja) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物 |
WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
WO2020203538A1 (ja) | 2019-03-29 | 2020-10-08 | 株式会社カネカ | 多能性幹細胞を含む細胞集団及びその製造方法 |
WO2020230832A1 (ja) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
CN115348959A (zh) * | 2019-11-25 | 2022-11-15 | 增益治疗股份有限公司 | 杂芳基化合物及其在与β-葡糖脑苷脂酶活性改变相关的病症中的治疗用途 |
WO2021105908A1 (en) * | 2019-11-25 | 2021-06-03 | Gain Therapeutics Sa | Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase |
WO2021220132A1 (en) | 2020-04-27 | 2021-11-04 | Novartis Ag | Methods and compositions for ocular cell therapy |
WO2022128853A1 (en) | 2020-12-15 | 2022-06-23 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
WO2022128851A1 (en) | 2020-12-15 | 2022-06-23 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
WO2022128843A1 (en) | 2020-12-15 | 2022-06-23 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho- kinase inhibitors |
WO2022128848A1 (en) | 2020-12-15 | 2022-06-23 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho-kinase inhibitors |
WO2022149616A1 (ja) | 2021-01-08 | 2022-07-14 | 国立大学法人京都大学 | ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法 |
WO2022216911A1 (en) | 2021-04-07 | 2022-10-13 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
WO2022259721A1 (ja) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | 間葉系幹細胞の製造方法 |
WO2023017848A1 (ja) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法 |
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2023110700A1 (en) | 2021-12-13 | 2023-06-22 | Chiesi Farmaceutici S.P.A. | Dihydrofuropyridine derivatives as rho-kinase inhibitors |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Also Published As
Publication number | Publication date |
---|---|
ES2273047T3 (es) | 2007-05-01 |
JP2006506458A (ja) | 2006-02-23 |
EP1562935A1 (de) | 2005-08-17 |
AU2003278088A1 (en) | 2004-05-25 |
CA2503646C (en) | 2011-09-27 |
EP1562935B1 (de) | 2006-09-06 |
US20060241127A1 (en) | 2006-10-26 |
DE50304983D1 (de) | 2006-10-19 |
US7737153B2 (en) | 2010-06-15 |
CA2503646A1 (en) | 2004-05-13 |
JP4681451B2 (ja) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1562935B1 (de) | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren | |
EP1742945B1 (de) | Substituierte phenylaminopyrimidine | |
EP1709043B1 (de) | Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen | |
EP1751153B1 (de) | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer | |
KR101311757B1 (ko) | 2-아미노-7,8-디히드로-6h-피리도[4,3-d]피리미딘-5-온 | |
KR101812390B1 (ko) | 키나제 억제제로서의 치환된 트리시클릭 벤즈이미다졸 | |
EP1515965B1 (de) | Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren | |
KR20160135283A (ko) | 5-치환된 인다졸-3-카르복스아미드 및 이의 제조 및 용도 | |
JP2004515544A (ja) | キナゾリノン誘導体 | |
KR20160063026A (ko) | 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체 | |
WO2003051877A1 (en) | 2-substituted pyrrolo[2.1-a]isoquinolines against cancer | |
AU2020406824A1 (en) | Novel pyrimidine derivative and use thereof | |
KR101667277B1 (ko) | Trpm8 수용체 조절제로서 유용한 치환된 아자-바이사이클릭 이미다졸 유도체 | |
EP1655297A1 (de) | Nicotinamidpyridinharnstoffe als Kinaseinhibitoren des Rezeptors des vaskulären endothelialen Wachstumsfaktors (VEGF) | |
DE10332232A1 (de) | Heteroaryloxy-substituierte Phenylaminopyrimidine | |
WO2006110447A2 (en) | Pyrimidine derivatives and their use in the treatment of cancer | |
CN116669725A (zh) | 新型氨基吡啶及其在治疗癌症中的用途 | |
DE102004060752A1 (de) | Hetaryloxy-substituierte Phenylaminopyrimidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003769398 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2503646 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005501803 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003769398 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006241127 Country of ref document: US Ref document number: 10531889 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003769398 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10531889 Country of ref document: US |